13 December 2016 - A novel human recombinant follicle stimulating hormone administered using an individualised dosing regimen.

Ferring Pharmaceuticals announced today that the European Commission has granted marketing authorisation for Rekovelle (follitropin delta), a human recombinant follicle stimulating hormone, for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies, such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.

Read Ferring Pharmaceuticals press release